1. pregnancy or breastfeeding. 2. suspected of active viral or bacterial infection other than sars-cov-2. 3. participation in another interventional study with potentially conflicting medication within 30 days before screening. 4. severely immunocompromised people (data gathered from preexisting medical records and history taking). this exclusion category includes: 1. subjects with human immunodeficiency virus (hiv-1). 2. neutropenic subjects with less than 500 neutrophils / mm3. 3. subjects with solid organ transplantation. 4. subjects with bone marrow transplantation. 5. subjects undergoing chemotherapy. 6. subjects with primary immunodeficiency. 7. severe lymphopenia with less than 400 lymphocytes / mm3. 8. treatment with any anti-cytokine therapy. 9. oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months. 5. malignancy, or active solid or non-solid lymphoma from the previous two years. 6. bcg vaccination in the last 10 years. 7. chloroquine or hydroxychloroquine administration in the last two weeks 8. soy allergy 9. direct involvement in the design or execution of the mycovind clinical trial. 10. do not have a smartphone. 11. detection by the investigator of lack of knowledge or willingness to participate and comply with all requirements of the protocol. 12. any other findings that, at the discretion of the investigator, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of probiotics.

1. pregnancy or breastfeeding. 2. suspected of active viral or bacterial infection other than sars-cov-2. 3. participation in another interventional study with potentially conflicting medication within 30 days before screening. 4. severely immunocompromised people (data gathered from preexisting medical records and history taking). this exclusion category includes: 1. subjects with human immunodeficiency virus (hiv-1). 2. neutropenic subjects with less than 500 neutrophils / mm3. 3. subjects with solid organ transplantation. 4. subjects with bone marrow transplantation. 5. subjects undergoing chemotherapy. 6. subjects with primary immunodeficiency. 7. severe lymphopenia with less than 400 lymphocytes / mm3. 8. treatment with any anti-cytokine therapy. 9. oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months. 5. malignancy, or active solid or non-solid lymphoma from the previous two years. 6. bcg vaccination in the last 10 years. 7. chloroquine or hydroxychloroquine administration in the last two weeks 8. soy allergy 9. direct involvement in the design or execution of the mycovind clinical trial. 10. do not have a smartphone. 11. detection by the investigator of lack of knowledge or willingness to participate and comply with all requirements of the protocol. 12. any other findings that, at the discretion of the investigator, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of probiotics.

pregnancy or breastfeeding. suspected of active viral or bacterial infection other than sars-cov-2. participation in another interventional study with potentially conflicting medication within 30 days before screening. severely immunocompromised people (data gathered from preexisting medical records and history taking). this exclusion category includes: subjects with human immunodeficiency virus (hiv-1). neutropenic subjects with less than 500 neutrophils / mm3. subjects with solid organ transplantation. subjects with bone marrow transplantation. subjects undergoing chemotherapy. subjects with primary immunodeficiency. severe lymphopenia with less than 400 lymphocytes / mm3. treatment with any anti-cytokine therapy. oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months. malignancy, or active solid or non-solid lymphoma from the previous two years. bcg vaccination in the last 10 years. chloroquine or hydroxychloroquine administration in the last two weeks soy allergy direct involvement in the design or execution of the mycovind clinical trial. do not have a smartphone. detection by the investigator of lack of knowledge or willingness to participate and comply with all requirements of the protocol. any other findings that, at the discretion of the investigator, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of probiotics.

pregnancy or breastfeeding. suspected of active viral or bacterial infection other than sars-cov-2. participation in another interventional study with potentially conflicting medication within 30 days before screening. severely immunocompromised people (data gathered from preexisting medical records and history taking). this exclusion category includes: subjects with human immunodeficiency virus (hiv-1). neutropenic subjects with less than 500 neutrophils / mm3. subjects with solid organ transplantation. subjects with bone marrow transplantation. subjects undergoing chemotherapy. subjects with primary immunodeficiency. severe lymphopenia with less than 400 lymphocytes / mm3. treatment with any anti-cytokine therapy. oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months. malignancy, or active solid or non-solid lymphoma from the previous two years. bcg vaccination in the last 10 years. chloroquine or hydroxychloroquine administration in the last two weeks soy allergy direct involvement in the design or execution of the mycovind clinical trial. do not have a smartphone. detection by the investigator of lack of knowledge or willingness to participate and comply with all requirements of the protocol. any other findings that, at the discretion of the investigator, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of probiotics.

1. pregnancy or breastfeeding. 2. suspected of active viral or bacterial infection other than sars-cov-2. 3. participation in another interventional study with potentially conflicting medication within 30 days before screening. 4. severely immunocompromised people (data gathered from preexisting medical records and history taking). this exclusion category includes: 1. subjects with human immunodeficiency virus (hiv-1). 2. neutropenic subjects with less than 500 neutrophils / mm3. 3. subjects with solid organ transplantation. 4. subjects with bone marrow transplantation. 5. subjects undergoing chemotherapy. 6. subjects with primary immunodeficiency. 7. severe lymphopenia with less than 400 lymphocytes / mm3. 8. treatment with any anti-cytokine therapy. 9. oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months. 5. malignancy, or active solid or non-solid lymphoma from the previous two years. 6. bcg vaccination in the last 10 years. 7. chloroquine or hydroxychloroquine administration in the last two weeks 8. soy allergy 9. direct involvement in the design or execution of the mycovind clinical trial. 10. do not have a smartphone. 11. detection by the investigator of lack of knowledge or willingness to participate and comply with all requirements of the protocol. 12. any other findings that, at the discretion of the investigator, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of probiotics.

1. pregnancy or breastfeeding. 2. suspected of active viral or bacterial infection other than sars-cov-2. 3. participation in another interventional study with potentially conflicting medication within 30 days before screening. 4. severely immunocompromised people (data gathered from preexisting medical records and history taking). this exclusion category includes: 1. subjects with human immunodeficiency virus (hiv-1). 2. neutropenic subjects with less than 500 neutrophils / mm3. 3. subjects with solid organ transplantation. 4. subjects with bone marrow transplantation. 5. subjects undergoing chemotherapy. 6. subjects with primary immunodeficiency. 7. severe lymphopenia with less than 400 lymphocytes / mm3. 8. treatment with any anti-cytokine therapy. 9. oral treatment with steroids, defined as daily doses of 10 mg prednisone or equivalent for more than 3 months. 5. malignancy, or active solid or non-solid lymphoma from the previous two years. 6. bcg vaccination in the last 10 years. 7. chloroquine or hydroxychloroquine administration in the last two weeks 8. soy allergy 9. direct involvement in the design or execution of the mycovind clinical trial. 10. do not have a smartphone. 11. detection by the investigator of lack of knowledge or willingness to participate and comply with all requirements of the protocol. 12. any other findings that, at the discretion of the investigator, may compromise compliance with the protocol or that may influence significantly the interpretation or the results of the effects of probiotics.